Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Takes Calistoga To Boost Cancer Effort

This article was originally published in Start Up

Executive Summary

Gilead Sciences Inc.’s recent acquisition of Calistoga Pharmaceuticals Inc. for $375 million up front is the richest deal yet for PI3K inhibitors, an emerging class of cancer drugs that many companies large and small are hotly pursuing.

You may also be interested in...



Baxter Locks Up European Rights To Onconova’s Late-Stage Cancer Drug Rigosertib

For an myelodysplastic syndrome and pancreatic cancer drug, the diversified pharma and device company paid $50 million upfront, plus a generous $515 million in milestones that could pay out before the drug is even commercialized.

VCs Applaud JOBS Act, But Will It Open Doors For Life Science Start-Ups?

“Emerging growth” start-ups will enjoy less regulation during their first five years as public companies, easing the burden on new listings while giving IPO prospects more leverage against buyers.

Eyeing Both A Partnership And An IPO, Aragon Takes $42M Series C

A well-connected fund that invests on behalf of a group of high-net-worth investors provides cash to complete a Phase II trial on prostate cancer drug ARN-509, and bring a breast cancer drug into the clinic.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel